Low serum vitamin D levels and recurrent inflammatory spinal cord disease

Archives of Neurology

Volumn 69, Issue 3, 2012, Pages 352-356

  Mealy, Maureen A ^a   Newsome, Scott ^a   Greenberg, Benjamin M ^b   Wingerchuk, Dean ^c   Calabresi, Peter ^a   Levy, Michael ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D;

ADOLESCENT; ADULT; AFRICAN AMERICAN; AGED; ARTICLE; ASSISTIVE TECHNOLOGY DEVICE; AUTUMN; BILATERAL ASSISTANCE; CAUCASIAN; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GROUPS BY AGE; HUMAN; IDIOPATHIC DISEASE; INFANT; MAJOR CLINICAL STUDY; MALE; MONOPHASIC SPINAL CORD DISEASE; PATIENT MOBILITY; PRESCHOOL CHILD; PRIORITY JOURNAL; RACE DIFFERENCE; RECURRENT DISEASE; RECURRENT INFLAMMATORY SPINAL CORD DISEASE; RELAPSE; RETROSPECTIVE STUDY; SCHOOL CHILD; SEX; SEX DIFFERENCE; SPINAL CORD DISEASE; SPRING; SUMMER; UNASSISTED; UNILATERAL ASSISTANCE; UNITED STATES; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION; WHEELCHAIR; WINTER;

25-HYDROXYVITAMIN D 2; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AGING; CALCIFEDIOL; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFANT; MALE; MIDDLE AGED; MOBILITY LIMITATION; MYELITIS; MYELITIS, TRANSVERSE; NEUROMYELITIS OPTICA; RECURRENCE; RETROSPECTIVE STUDIES; SEASONS; VITAMIN D; VITAMIN D DEFICIENCY; YOUNG ADULT;

EID: 84858587646     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2011.1974     Document Type: Article

References (30)

1. Ascherio A, Munger KL, Simon KC. Vitamin D and multiple sclerosis. Lancet Neurol. 2010;9(6):599-612.
2. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA. 2006;296(23):2832-2838. (Pubitemid 44969183)
3. Smolders J, Menheere P, Kessels A, Damoiseaux J, Hupperts R. Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult Scler. 2008;14(9):1220-1224.
4. Burton JM, Kimball S, Vieth R, et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis [published corrections appear in Neurology. 2010;75(5):480 and Neurology. 2010;75(11):1029]. Neurology. 2010; 74(23):1852-1859.
5. van Etten E, Gysemans C, Branisteanu DD, et al. Novel insights in the immune function of the vitamin D system: synergism with interferon-beta. J Steroid Biochem Mol Biol. 2007;103(3-5):546-551. (Pubitemid 46401359)
6. Mahon BD, Gordon SA, Cruz J, Cosman F, Cantorna MT. Cytokine profile in patients with multiple sclerosis following vitaminDsupplementation. JNeuroimmunol. 2003;134(1-2):128-132. (Pubitemid 36050838)
7. Lemire JM, Archer DC. 1,25-dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J Clin Invest. 1991; 87(3):1103-1107.
8. Kaplin AIMD, Krishnan C, Deshpande DM, Pardo CA, Kerr DA. Diagnosis and management of acute myelopathies. Neurologist. 2005;11(1):2-18. (Pubitemid 40111067)
9. Hummers LK, Krishnan C, Casciola-Rosen L, et al. Recurrent transverse myelitis associates with anti-Ro (SSA) autoantibodies. Neurology. 2004;62(1):147-149. (Pubitemid 38082893)
10. Wingerchuk DM. Diagnosis and treatment of neuromyelitis optica. Neurologist. 2007;13(1):2-11. (Pubitemid 46095579)
11. McKeon A, Fryer JP, Apiwattanakul M, et al. Diagnosis of neuromyelitis spectrum disorders: comparative sensitivities and specificities of immunohistochemical and immunoprecipitation assays. Arch Neurol. 2009;66(9):1134-1138.
12. Ishizu T, Osoegawa M, Mei FJ, et al. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain. 2005;128(pt 5):988-1002. (Pubitemid 40675455)
13. Kira J. Neuromyelitis optica and opticospinal multiple sclerosis: mechanisms and pathogenesis. Pathophysiology. 2011;18(1):69-79.
14. Graber JJ, Allie SR, Mullen KM, et al. Interleukin-17 in transverse myelitis and multiple sclerosis. J Neuroimmunol. 2008;196(1-2):124-132.
15. Pedersen LB, Nashold FE, Spach KM, Hayes CE. 1,25-dihydroxyvitamin D3 reverses experimental autoimmune encephalomyelitis by inhibiting chemokine synthesis and monocyte trafficking. J Neurosci Res. 2007;85(11):2480-2490. (Pubitemid 47204762)
16. Garcion E, Sindji L, Nataf S, Brachet P, Darcy F, Montero-Menei CN. Treatment of experimental autoimmune encephalomyelitis in rat by 1,25-dihydroxyvitamin D3 leads to early effects within the central nervous system. Acta Neuropathol. 2003;105(5):438-448. (Pubitemid 36798839)
17. Gannagé-Yared MH, Azoury M, Mansour I, Baddoura R, Halaby G, Naaman R. Effects of a short-term calcium and vitamin D treatment on serum cytokines, bone markers, insulin and lipid concentrations in healthy post-menopausal women. J Endocrinol Invest. 2003;26(8):748-753. (Pubitemid 37451753)
18. Dickie LJ, Church LD, Coulthard LR, Mathews RJ, Emery P, McDermott MF. Vitamin D3 down-regulates intracellular Toll-like receptor 9 expression and Tolllike receptor 9-induced IL-6 production in human monocytes. Rheumatology (Oxford). 2010;49(8):1466-1471.
19. Correale J, Ysrraelit MC, Gaitán MI. Immunomodulatory effects of vitamin D in multiple sclerosis. Brain. 2009;132(pt 5):1146-1160.
20. Tang J, Zhou R, Luger D, et al. Calcitriol suppresses antiretinal autoimmunity through inhibitory effects on the Th17 effector response. J Immunol. 2009; 182(8):4624-4632.
21. Prietl B, Pilz S, Wolf M, et al. Vitamin D supplementation and regulatory T cells in apparently healthy subjects: vitamin D treatment for autoimmune diseases? Isr Med Assoc J. 2010;12(3):136-139.
22. Lund B, Sørensen OH. Measurement of 25-hydroxyvitamin D in serum and its relation to sunshine, age and vitamin D intake in the Danish population. Scand J Clin Lab Invest. 1979;39(1):23-30. (Pubitemid 10136889)
23. Yetley EA. Assessing vitamin D in the US population. Am J Clin Nutr. 2008;88(2):558S-564S.
24. Beretich BD, Beretich TM. Explaining multiple sclerosis prevalence by ultraviolet exposure: a geospatial analysis. Mult Scler. 2009;15(8):891-898.
25. Gleicher N, Barad DH. Gender as risk factor for autoimmune diseases. J Autoimmun. 2007;28(1):1-6. (Pubitemid 46274179)
26. Dooley MA, Hogan SL. Environmental epidemiology and risk factors for autoimmune disease. Curr Opin Rheumatol. 2003;15(2):99-103. (Pubitemid 36250287)
27. Houghton LA, Vieth R. The case against ergocalciferol (vitamin D2) as a vitamin supplement. Am J Clin Nutr. 2006;84(4):694-697. (Pubitemid 44715649)
28. Rajakumar K, de las Heras J, Chen TC, Lee S, Holick MF, Arslanian SA. Vitamin D status, adiposity, and lipids in black American and Caucasian children. J Clin Endocrinol Metab. 2011;96(5):1560-1567.
29. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502- 1517.
30. Holick MF. Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am J Clin Nutr. 2004;79(3):362-371. (Pubitemid 41115577)